Loading publications…
The last 5 uploaded publications
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma
Li Zhou, Milton Barros, Edward Hsiao, Zeynep Eroglu, Shahneen Sandhu, Igor Samoylenko, Serigne Lo, Matteo S Carlino, George Au‐Yeung, Maria Gonzalez, Andrew J. Spillane, Thomas E Pennington, Kerwin F Shannon, Rony Kapoor, Elizabeth M. Burton, Hussein A. Tawbi, Rodabe N. Amaria, Christian U. Blank, João Pedreira Duprat Neto, Rafaela Brito de Paula, David E Gyorki, R.P.M. Saw, Sydney Ch'ng, Robert V. Rawson, Richard A. Scolyer, Inês Pires da Silva, Alexander C J van Akkooi, Georgina V Long, Alexander M. Menzies (2025). FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. , 13(3), DOI: https://doi.org/10.1136/jitc-2025-011483.
Article62 days agoLBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial
M.W. Lucas, A.M. Menzies, Marta López‐Yurda, Richard A. Scolyer, B. van de Wiel, R.P.M. Saw, W. Van Houdt, Nigel Maher, A. Torres Acosta, M. Boers-Sonderen, G. Hospers, M.S. Carlino, Jan Willem de Groot, E. Kapiteijn, K. Suijkerbuijk, P. Rutkowski, Shahneen Sandhu, Astrid A.M. van der Veldt, G.V. Long, C.U. Blank (2024). LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial. , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.2283.
Article62 days agoLBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
G.V. Long, C.U. Blank, R. Amaria, Tina J. Hieken, Shahneen Sandhu, M.J. Barros, T.C.C. Mitchell, Zeynep Eroglu, Igor Samoylenko, P. Rutkowski, D.B. Johnson, I. Pires da Silva, Kyle A. Perry, H.A. Tawbi, Matthew S. Block, P.A. Ascierto, Eric Burton, Alexander C.J. van Akkooi, Richard A. Scolyer, A.M. Menzies (2024). LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). , 35, DOI: https://doi.org/10.1016/j.annonc.2024.08.2282.
Article62 days agoNeoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
Christian U. Blank, Minke W. Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, Alex Torres Acosta, Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid Aplonia Maria Van Der Veldt, Georgina V. Long (2024). Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. , 42(17_suppl), DOI: https://doi.org/10.1200/jco.2024.42.17_suppl.lba2.
Article62 days agoSupplementary Figure S2 from UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas
Stephen Q. Wong, Kelly Waldeck, Ismael A. Vergara, Jan Schröder, Jason Madore, James S. Wilmott, Andrew J. Colebatch, Ricardo De Paoli‐Iseppi, Jason Li, Richard Lupat, Timothy Semple, Gisela Mir Arnau, Andrew Fellowes, J. Helen Leonard, George Hruby, Graham J. Mann, John F. Thompson, Carleen Cullinane, Meredith Johnston, Mark Shackleton, Shahneen Sandhu, David D.L. Bowtell, Ricky W. Johnstone, Stephen B. Fox, Grant A. McArthur, Anthony T. Papenfuss, Richard A. Scolyer, Anthony J. Gill, Rodney J. Hicks, Richard W. Tothill (2023). Supplementary Figure S2 from UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. , DOI: https://doi.org/10.1158/0008-5472.22408173.v1.
Preprint62 days ago